Penbrook Management LLC Exagen Inc. Transaction History

Penbrook Management LLC

$137 Million
Q4 2024

A detailed history of Penbrook Management LLC transactions in Exagen Inc. stock. As of the latest transaction made, Penbrook Management LLC holds 44,594 shares of XGN stock, worth $159,646. This represents 0.13% of its overall portfolio holdings.

Number of Shares

44,594

Previous 62,955 29.17%

Holding current value

$159,646

Previous $194,000 6.19%

% of portfolio

0.13%

Previous 0.13%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 23, 2025	SELL	$2.43 - $6.0 $44,617 - $110,166	-18,361 Reduced 29.17%	44,594 $182,000
Q3 2024 Oct 15, 2024	SELL	$1.74 - $3.42 $11,310 - $22,230	-6,500 Reduced 9.36%	62,955 $194,000
Q2 2024 Jul 24, 2024	SELL	$1.36 - $2.05 $9,866 - $14,872	-7,255 Reduced 9.46%	69,455 $126,000
Q1 2024 Apr 18, 2024	BUY	$1.42 - $2.3 $1,420 - $2,300	1,000 Added 1.32%	76,710 $121,000
Q4 2023 Jan 16, 2024	BUY	$1.45 - $2.39 $3,335 - $5,497	2,300 Added 3.13%	75,710 $150,000
Q3 2023 Oct 10, 2023	SELL	$2.24 - $2.93 $1,344 - $1,758	-600 Reduced 0.81%	73,410 $177,000
Q4 2022 Jan 24, 2023	SELL	$2.1 - $3.4 $27,279 - $44,166	-12,990 Reduced 14.93%	74,010 $0
Q3 2022 Oct 31, 2022	SELL	$2.69 - $8.68 $2,959 - $9,548	-1,100 Reduced 1.25%	87,000 $236,000
Q2 2022 Jul 29, 2022	SELL	$4.18 - $7.74 $2,090 - $3,870	-500 Reduced 0.56%	88,100 $506,000
Q4 2021 Jan 10, 2022	BUY	$8.97 - $14.08 $7,624 - $11,968	850 Added 0.97%	88,600 $1.03 Million
Q3 2021 Oct 26, 2021	BUY	$10.25 - $15.21 $899,437 - $1.33 Million	87,750 New	87,750 $1.19 Million

Others Institutions Holding XGN

# of Institutions

Shares Held

6.05M

Call Options Held

1.1K

Put Options Held

6.4K

View Full List

About EXAGEN INC.

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $58.2M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

More about XGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Penbrook Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penbrook Management LLC with notifications on news.

Account

Penbrook Management LLC Exagen Inc. Transaction History